Irbesartán Alter

Irbesartan, the active ingredient in Irbesartán Alter, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartán Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the ARB class and is used to treat conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure and reduces the risk of cardiovascular complications. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes by decreasing intraglomerular pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nasal congestion: blockage or runny nose. - Diarrhea: loose stools occurring intermittently. - Elevated potassium: mild increase in serum potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Acute renal failure: sudden loss of kidney function, indicated by reduced urine output. - Hyperkalemia: significant rise in blood potassium that can affect heart rhythm. - Hepatic injury: abnormal liver enzyme elevations or hepatitis. - Severe hypotension: abrupt, dangerous drop in blood pressure.

Patients should be monitored for safety and appropriate use. - Monitor blood pressure: check regularly to ensure therapeutic control. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium levels, to avoid hyperkalemia. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in pregnancy: drug may harm the fetus; discontinue if pregnancy is confirmed. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Irbesartan can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase renal risk. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use raises the chance of angioedema and renal impairment. - Lithium: increased lithium concentrations can lead to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - NSAIDs: can reduce antihypertensive efficacy and affect renal function. - CYP2C9 inhibitors (e.g., fluconazole): may modestly increase irbesartan plasma levels.